This report presents the results of interviews conducted with 60 trained DMPA service providers from seven of the ten local government units (LGUs) covered by Phase I of the Philippine Department of Health\u27s DMPA Reintroduction Program. DMPA, or Depot-medroxyprogesterone acetate, is an injectable contraceptive commonly known as Depo-Provera. The interviews were undertaken as part of the DMPA Monitoring and Follow-up Studies sponsored by the Population Council under the Asia and Near East Operations Research and Technical Assistance (ANE OR/TA) Project. While the monitoring study and the follow-up survey focused on DMPA users and dropouts, this study centered on the service provider. The DMPA Reintroduction Program was launched by the DOH in April 1994 by the Philippine Bureau of Food and Drugs. The program aims to reintroduce DMPA into the Philippine Family Planning Program through training local-level doctors, nurses, and midwives as service providers, and providing free DMPA services in selected public health facilities